poisar

Stocks · News reference

enGene Updates Pivotal Bladder Cancer Data and Announces Executive Appointments

Fiscal.ai

enGene Therapeutics announced updated clinical data for its lead candidate, detalimogene voraplasmid, and the appointment of a new Chief Medical Officer and Chief Legal and Administrative Officer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate

    enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from